Sarah Blagden

Sarah Blagden received a medical degree (MBBS) at Charing Cross and Westminster Medical School, University of London in 1994.[4]

In 2004 she received a PhD (as CRUK Clinical Fellow) at Cambridge University[4]

After Blagden completed her medical training and subsequent specialist training in Medical Oncology at Addenbrooke's Hospital in Cambridge and the Royal Mardsden Hospital she went on to hold a Clinical Fellowship at the Institute of Cancer Research's Drug Development Unit.[1] She was appointed to Senior Lecturer and Honorary Consultant at the Imperial College in 2006 and became a Director of Imperial's Early Cancer Trials Unit and was able to established her own laboratory for studying the dysregulation of mRNA translation in cancer.[1]

Blagden was also a chief/Principal investigator for a number of national and international clinical studies.[1] She is a Researcher and Associate Professor of Experimental Cancer therapeutics at the University of Oxford in the department of oncology[1][2]

• CRUK Junior Clinician Scientist PhD fellowship in 1999 at Cambridge University[1]
• CRUK clinical Fellow PhD in 2004 at Cambridge University.[4]
• Fellowship of Royal College Physicians in 2010[4]